Codexis Reports Second Quarter 2022 Financial Results
At Codexis, we strive to discover and develop more effective therapeutics, offer healthier choices, innovate sustainable processes and products, and reduce waste – all to create a brighter future.
These goals are grand but not beyond reach. Together with our business partners and loyal customers, we can make them a reality.
A paper authored by Merck and Codexis in the June 2022 issue of the peer-reviewed journal Science, details the development of a suite of enzymes and their application for site-selective synthesis of insulin bioconjugates.View Paper